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Abstract 
Stimuli responsive polymers are an efficient means of targeted therapy.  Compared to 
conventional agents, they increase bioavailability and efficacy.  In particular, polymer hydrogel 
nanoparticles (NPs) can be designed to respond when exposed to a specific environmental 
stimulus such as pH or temperature.  However, targeting a specific metabolite as the trigger for 
stimuli response could further elevate selectivity and create a new class of bioresponsive 
materials.  In this work we describe an N-isopropylacrylamide (NIPAm) NP that responds to a 
specific metabolite characteristic of a hypoxic environment found in cancerous tumors.  NIPAm 
NPs were synthesized by copolymerization with an oxamate derivative, a known inhibitor of 
lactate dehydrogenase (LDH).  The oxamate functionalized NPs (OxNP) efficiently sequestered 
LDH to produce an OxNP-protein complex.  When exposed to elevated concentrations of lactic 
acid, a substrate of LDH and a metabolite characteristic of hypoxic tumor microenvironments, 
OxNP-LDH complexes swelled (65%).  The OxNP-LDH complexes were not responsive to 
structurally related small molecules.  This work demonstrates a proof of concept for tuning NP 
responsiveness by conjugation with a key protein to target a specific metabolite of disease.  
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Introduction  
 Drug delivery has been a high priority for researchers in academia and industry alike.  
Challenges arise from solubilizing drugs, maximizing bioavailability, and ensuring selectivity 
toward the tissues and organs that are to be treated.  However, combining these traits into a 
single vehicle remains elusive and has been a driving force for research.  Methods devised to 
address these problems include developing stimuli-responsive materials.  This strategy addresses 
the challenges of selectivity and if designed appropriately, can help increase bioavailability. 
 Various strategies have been investigated including systems responsive to changes in 
pH1-10, reducing or oxidizing environments11, disease associated enzymes12-16 or small 
molecules17, hypoxic environments18, mechanical cues19,20, and temperature21,22.  However, the 
relatively low incidence of clinical success would suggest there are still opportunities to improve 
performance.23,24  Other methods draw inspiration from biology.  Protein-polymer conjugates 
have made an impact in the scientific community as an attractive approach to address drug 
delivery.  These strategies consist of non-covalent, covalent, and supramolecular interactions 
between polymers and proteins.  Some examples involve protein cages, formation of polymer 
micelles around proteins, and synthesis of nanoparticles incorporating proteins into the 
backbone.25-32  All of these strategies have been used to enhance the success and selectivity of 
delivering biological agents as well as drugs. 
 The versatility of nanoparticles allows for a range of approaches to be employed. Protein-
nanoparticle complexes are of particular interest as treatments for various diseases, especially 
cancer.  The stimuli response of protein-nanoparticle complexes has depended on many of the 
previously mentioned strategies.  These studies have included adenosine-5’-triphosphate (ATP) 
and glucose responsive systems.33  Both the ATP and glucose systems rely on a concentration 
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gradient or an intra- and intercellular difference in concentration of these molecules.  The 
specificity of these systems is lacking in the sense that ATP and glucose are found throughout 
the body.  High local concentration of a specific molecule or metabolite that is a signature of a 
disease can provide a chemospecific target for therapeutic intervention.  However, there remains 
a compelling need to develop a responsive polymer-protein conjugated system designed around a 
specific disease associated metabolite.  Designing a protein-nanoparticle complex that responds 
to a metabolite of disease could provide an effective solution to the issue of selectivity.  By 
focusing on a molecule or metabolite that has distinctively high concentrations in the local area 
of disease, side effects can be minimized while maximizing therapeutic effects.   
There have been many studies describing the Warburg effect in cancer progression.  This 
phenomenon describes an accumulation of lactate, leading to a decrease in pH within the cancer 
microenvironment.34-36  The phenomenon is  attributed to cancer cells that predominantly utilize 
anaerobic glycolysis instead of oxidative phosphorylation. 34-36  Cancer usually exists under low 
oxygen, or hypoxic, conditions so cells must compensate for this impediment to energy 
production.  This leads to a lactate concentration higher than what is found under normoxic 
conditions.  Anaerobic glycolysis is performed in healthy tissues as well, most notably during 
exercise when a build-up of lactic acid occurs.  Healthy tissues have lactate concentrations 
between 0.5-2 mM37-39, while concentrations in tumor tissues range from 10-20 mM40-43 and up 
to 40 mM35,40.  The almost ten-fold increase in lactic acid lowers the pH from 7.4 to 6.0-7.044 an 
effect that has been taken advantage of by designing polymers that release anti-cancer drugs 
under acidic conditions. 34-36  However, there are organs with regions of low pH that are not 
associated with cancer, most notably the stomach and kidney.  A more chemospecific trigger, 
such as one that responds to high lactate concentrations, would be more effective. 
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 In this report, we describe hydrogel nanoparticles (NP) that are responsive to lactate at 
physiologically relevant concentrations.  To achieve this, we incorporated a known inhibitor of 
lactate dehydrogenase (LDH), oxamate, into the backbone of a hydrogel polymer. The polymer 
bound oxamate was used to bind LDH, present as a homomeric tetramer, non-covalently to the 
polymer and function as a cross-linker between the polymer NP and LDH.  We utilized N-
isopropylacrylamide (NIPAm) as the base monomer.  NIPAm was chosen due to its low affinity 
for plasma proteins, this minimizes any non-specific binding of proteins other than the one of 
interest.45   NIPAm polymers exhibit a lower critical solution temperature (LCST) at 
approximately 32 oC.  Below this temperature, the polymer is solvent swollen.  Increasing the 
temperature beyond 32 oC desolvates the particle, leading to a volume reduction.  Our design 
strategy was to incorporate LDH into the polymer in its solvent swollen state (< 32 oC) before 
raising the temperature to physiological conditions.   
Our LDH was based on the protein sequence of Bacillus stearothermophilus LDH, a 
thermally stable and well characterized protein that would be compatible with experimental 
Figure 1: Lactate responsive nanoparticle.  An inhibitor for LDH is incorporated into the NP.  When LDH 
is introduced, the inhibitor acts as a cross-linker between the particle and protein leading to a decrease in 
NP size.  Once the complex is introduced to lactate, the inhibitor is displaced and the cross-linking is 
eliminated.  This leads to a swelling of the particle. 
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conditions.  LDH is a homomeric tetramer with four binding sites and provides a nexus for cross-
linking by the polymer-bound oxamate (Figure 1).  This enzyme converts pyruvate into lactate, 
this is done at higher than normal rates within the tumor microenvironment so the cancer cells 
can utilize lactate fermentation.  However, this enzymatic reaction is reversible, and lactate can 
be converted back into pyruvate with the same enzyme.  The polymer-bound oxamate will non-
covalently bind LDH; when more than one oxamate binds to the homomeric tetramer, the result 
is cross-linking.  These cross-links will be competitively displaced by lactate upon entering an 
environment with elevated lactate levels.  The decreased cross-linking of the polymer to LDH 
endows the particle with a lactate responsiveness that results in NP swelling.  At appropriate 
loadings of inhibitor and LDH, one can tune the lactate responsiveness of the NP to the relevant 
physiological range of lactate in the local cancer environment. 
 
Experimental  
1H NMR spectra were recorded at 500 MHz, using a Bruker DRX 500 spectrometer. 13C NMR 
spectra were recorded at 125 MHz, using a Bruker DRX CRYO500 spectrometer. 1H NMR and 
13C NMR spectra were run in CDCl3 with shifts reported as δ values in ppm and referenced to 
residual solvent proton or carbon. Splitting patterns are abbreviated as follows: s = singlet, d = 
doublet, dd = doublet of doublets, t = triplet, q = quartet, quint = quintet, sext = sextet, sep = 
septet, m = multiplet, br = broad. 
 
General Procedures.  
Methylene chloride was obtained from a dry Solvent Dispensing System.  Chloroform was 
distilled and kept under nitrogen.  Amine bases were freshly distilled over CaH2 from a ketal 
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still. NIPAm was recrystallized from hexanes. All other commercial reagents were used as 
received. Reactions were monitored by thin layer chromatography using glass-backed EM 
Science Silica Gel 60 PF254 Plates. Flash chromatography was performed using EM Science 
Silica Gel 60 (230-400 mesh). All volatile solvents were removed, in vacuo, under reduced 
pressure using a Büchi rotary evaporator. 
 
Inhibitor Synthesis 
 
1-Boc-1,6 hexanediamine 2: A solution of 1,6-hexanediamine (11g, 100 mmol) in chloroform 
(26 mL) was cooled to 0 oC with an external ice bath then treated via dropwise addition over two 
hours with a solution of Boc anhydride (4.4 g, 20 mmol) in chloroform (20 mL).  Reaction was 
removed from ice and allowed to warm to room temperature.  After reacting overnight, the 
solution was filtered, filtrate concentrated in vacuo, re-dissolved in ethyl acetate, washed with 
brine (3 x), dried over MgSO4, filtered, then concentrated in vacuo.  Flash column 
chromatography was performed and eluted with methylene chloride treated with an equal volume 
of methanol:ammonium hydroxide solution then concentrated in vacuo to yield 4.5 g (81%) of a 
thick white oil. 1H, 13C NMR, and HRMS matched the literature values.46  
 
Oxamide ester 3: To a cooled solution of ethyl chlorooxoacetate (0.08 mL, 0.75 mmol) in 
chloroform (2 mL) at 0oC, a solution of 2 (165 mg, 0.75 mmol) and Hünig’s base (0.2 mL, 1.125 
mmol) in chloroform (3 mL) was added.  Reaction turned from clear to light yellow.  After 
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completion by TLC, solution was washed with 0.1 N HCl (1 x), washed with DI water (1 x), 
dried over MgSO4, filtered, and concentrated in vacuo.  Flash column chromatography was 
performed eluting with 4:6 hexanes to ethyl acetate to yield 156.6 mg (66%) of a light yellow oil. 
1H NMR (CDCl3-D + 0.05% TMS, 500 MHz): δ/ppm = 7.21 (s, 1H, NH), 4.57 (s, 1H, NH), 4.39 
(q, 2H, CH2-O), 3.39 (q, 2H, CH2-NH), 3.16 (d, 2H, CH2-NH), 1.5 (m, 12H, CH3), 1.35-1.47 (m, 
8H, CH2-CH2); 13C NMR (CDCl3-D + 0.05% TMS, Cryo 500 MHz): δ 160.9, 156.6, 156.0, 63.3, 
40.3, 39.7, 30.0, 29.1, 28.4, 26.3, 26.2, 14.0, 13.9; HRMS (ESI-TOF): m/z calcd for C15H28N2O5 
[M + Na]+ 339.1896; found 339.1892. 
 
Boc Deprotection 4: A solution of compound 3 (24 mg, 0.079 mmol) in methylene chloride (0.3 
mL) was treated with TFA (0.2 mL, 2.7 mmol) at room temperature.  The reaction was 
monitored by TLC and finished in 30 min. Solvent was removed to produce a TFA salt, 20 mg 
(80% yield). 1H NMR (CDCl3-D + 0.05% TMS, 500 MHz): δ/ppm = 4.42 (q, 2H), 3.43 (m, 2H), 
3.17 (m, 2H) 1.79-1.54 (m, 13H); 13C NMR (CDCl3-D, Cryo 500 MHz): δ 158.8, 158.5, 117.0, 
114.7, 62.1, 62.0, 61.9, 54.4, 54.1, 13.35; HRMS (ESI-TOF): m/z calcd for C10H20N2O3 [M + H]+ 
217.1552; found 217.1550. 
 
Acryloylation 5: Et3N (0.65 mL, 4.5 mmol) was added to compound 4 (125 mg, 0.38 mmol) at 
0oC. Then, a solution of acryloyl chloride (36 µL, 0.45 mmol) in CH2Cl2 (5 mL) was added and 
stirred for 1h at 0oC.  The reaction then came to rt and left to stir o/n.  Reaction was complete by 
TLC (ethyl acetate, Rf = 0.25) and washed with NH4Cl (1x), NaHCO3 (1x), NaCl (1x), then dried 
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over MgSO4, filtered, and concentrated in vacuo. Flash column chromatography in EtOAc was 
performed to produce 54.8 mg (53 % yield).  1H NMR (CDCl3-D + 0.05% TMS, 500 MHz): 
δ/ppm = 7.22 (1H, b), 6.33 (dd, 1H, CHsp2), 6.16 (dd, 1H, CHsp2), 5.69 (dd, 1H, CHsp2), 4.41 (d, 
1H, NH), 3.39 (q, 2H, CH2-O), 1.65-1.45 (m, 11H, CH2-CH2); 13C NMR (CDCl3-D + 0.05% 
TMS, Cryo 500 MHz): δ 130.9, 126.3, 63.2, 39.5, 39.2, 29.4, 29.0, 26.2, 14.0; HRMS (ESI-
TOF): m/z calcd for C13H22N2O4 [M+Na]+ 293.1477; found 293.1475. 
  
Ester hydrolysis 6: KOH (18 mg, 0.32 mmol) was added to a solution of 5 (43 mg, 0.16 mmol) in 
MeOH (2 mL) at rt.  Reaction complete by TLC (ethyl acetate) after 10 min (Rf = 0). Reaction 
mixture was acidified with 5 N HCl. Solvent removed to produce a white solid (quantitative 
yield).  1H NMR (CDCl3-D + 0.05% TMS, 500 MHz): δ/ppm = 8.83 (s, 1H), 8.11 (s, 1H), 6.2 
(dd, 1H, CHsp2), 6.09 (dd, 1H), 5.58 (dd, 1H, CHsp2), 3.11 (m, 4H, CH2) 1.44-1.28 (m, 8H, CH2); 
13C NMR (CDCl3-D +0.05% TMS, Cryo 500 MHz): δ 128.8, 31.9. 29.4, 28.47, 26.1, 22.7, 14.1; 
HRMS (ESI-TOF): m/z calcd for C11H18N2O4 [M-H]- 241.1188; found 241.1188. 
 
OxNP Characterization 
DLS was run using OxNPs diluted 10-fold into nanopure water.  Samples at 37 oC were 
equilibrated for 2 min before measuring.  Molecular weight of nanoparticles was determined 
using SEC-MALS (Malvern Viskotek GPC/SEC triple detection system).  The system was run in 
PBS (10 mM phosphate, 50 mM NaCl). The column (Viscotek A7000) was heated to 30 oC and 
the system was calibrated to a 500 kDa pullulan standard.  Nanoparticle samples were prepared 
by dialyzing in PBS overnight.  The OxNP sample was diluted into PBS (2.5 mg/mL) and 
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injected onto the column.  Injections of 40 µL were used with a flow rate of 1 mL/min.  The Mn 
was determined to be 2.276 x 108 and Mw was 2.863 x 108 with a PDI of 1.26. 
 
Cloning of LDH gene 
DNA encoding wtLDH from B. stearothermophilus with a N-terminal His6X tag was 
synthesized by Integrated DNA Technologies using sequences optimized for E. coli expression. 
B. stearothermophilus LDH was selected due to its structural stability at elevated temperature. 
The gene was ligated into Blunt Topo vector, transformed into E. coli (DH5α) cells, and 
sequence confirmed with standard Sanger’s sequencing (GeneWiz).  wtLDH fragment of the 
wtLDH-TOPO vector was digested with BamHI and NdeI, extracted from a 0.7% agarose gel 
(GeneJET kit), and ligated into a BamHI- and NdeI-digested pET11a vector. The ligated plasmid 
was co-transformed into BL21(DE3) E. coli cells together with a pGRO7 chaperone protein 
plasmid.  
 
Purification of LDH  
Single colonies of co-transformed BL21(DE3) cells were picked and incubated overnight 
at 37°C for 16-18 hrs, and overnights were reinoculated into 1 L of LB culture containing 100 
µg/ml ampicillin, 50 µg/ml chloramphenicol and 1 mM arabinose (to induce the expression of 
GroEL/ES chaperone proteins). Once the OD600 of the culture reached 0.6-0.7, the LDH 
expression was induced with 1 mM IPTG for 3 hrs, and cells were harvested.  Cells were 
resuspended in breaking buffer and lysed in French pressure cell. Cell debris and insoluble 
fractions were removed using ultracentrifuge, and soluble fractions were purified using HisPur 
Ni-NTA affinity column following the product protocols. Samples of each fraction from the 
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affinity column were run on SDS-PAGE. The elution fractions with soluble LDH proteins were 
combined and exchanged into phosphate buffer using Zeba Desalting columns. The 
concentration of the purified LDH was obtained with a micro BCA Kit and stored at -80 °C.  
 
Protein Characterization 
Characterization of LDH was based on prior protocols for thermophilic proteins derived 
from B. stearothermophilus.47 In summary, purified LDH was run on 12% SDS-PAGE gel to 
examine the presence of impurities during and after purification. Mass spectroscopy was also 
performed (Waters Quattro Premier XE) to verify molecular weight of purified LDH. The 
secondary structure and thermostability of LDH were obtained following the protocol of Dalmau 
et al.47 Jasco 810 spectropolarimeter equipped with Jasco Peltier temperature controller (Jasco, 
Easton, MD) were used to measure the far-UV circular dichroism (CD).  LDH proteins were 
examined at a concentration of 0.06 mg/ml in 50 mM potassium phosphate and 100 mM NaCl.  
Samples were scanned between 200 and 260 nm at 25 °C at scanning speed of 10 nm/min in 0.1 
cm pathlength quartz cells.  
Thawed cells were resuspended in buffer (20 mM Tris pH 8.7, 0.02% sodium azide, 2 
U/mL DNase, 2 U/mL RNase, 1 mM MgCl2 and 1 mM PMSF) and lysed in a French pressure 
cell (Thermo Scientific, Milford, MA). The insoluble fraction was removed by 
ultracentrifugation. The resulting supernatant was heated at 70 oC for 20 min and the native, 
denatured E. coli protein aggregates were removed by centrifugation. The recovered supernatant 
was loaded onto a HiPrep Q-sepha rose anion exchange column (GE Healthcare, Piscataway, NJ) 
previously equilibrated with Tris buffer (20 mM Tris pH 8.7, 0.02% sodium azide, and 5 mM 
EDTA). 
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LDH Kinetics  
Protocols for determining Kcat and Km of LDH were based on previous studies by Clarke 
et al.48 Enzyme kinetics were measured by absorbance increases at 340 nm in the generation of 
NADH. All assays were done at 25 °C and in 100 mM triethanolamine hydrochloride buffer.  
Enzyme at 100 nM was mixed with 10 mM NAD+ and 20 mM FBP with varying lactate 
concentrations.  The initial slope of the absorbance vs. time was obtained for a range of lactate 
concentrations. This initial slope vs. concentration of lactate was plotted in GraphPad Prism and 
kinetic parameters (Km and kcat) were determined using a non-linear curve fit to the Michaelis-
Menten equation.  
 
Quantification of LDH Uptake  
A 1 mL sample of NP (0.4 mg/mL), FBP (1 mM), NAD+ (1 mM), and LDH (0.35 
mg/mL) was prepared in nanopure water.  Control samples consisted of NIPAm NPs (0.4 
mg/mL) with LDH (0.35 mg/mL) and FBP (1 mM).  After LDH was incubated with its 
coenzymes in water (1 min), NP was added.  After incubating at rt for 30 min, the samples were 
heated in a water bath at 37 oC for 10 min followed by centrifugation for 10 min at 14,000 rpm.  
For samples that were not incubated at 37 oC, they incubated at room temperature for an 
additional 10 min before centrifugation.  A white pellet formed at the bottom of the centrifuge 
tube and the supernatant was collected for fluorescence measurements.  Measurements were 
taken in quartz cuvettes (Starna Cells, 3mm) on a Cary Eclipse Spectrometer. Excitation was set 
to 280 nm and emission was measured from 290 nm to 400 nm, RFU measurements were 
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recorded at 342 nm.  A calibration curve of LDH was created starting at 0.01 mg/mL ending at 
0.35 mg/mL.  
The number of proteins bound to OxNPs was calculated using the wt/wt ratio of proteins 
bound to NPs.  Using the respective molecular weights (Mn for the OxNPs), the mole to mole 
ratio was calculated.  Using Avogadro’s number, we were then able to calculate the exact 
number of LDH proteins per OxNP.  Determining density of OxNPs required the molar mass of 
OxNPs and the Z-Average value to determine the volume.  The molar mass of one OxNP was 
calculated as stated above using Mn and Avogadro’s number, this value was then divided by the 
volume of an OxNP.  To determine the percent volume of OxNP taken up by LDH, we divided 
the volume of 1000 LDH proteins by the volume of OxNP.  The volume of LDH was calculated 
using the mass of one LDH protein divided by its density.  The mass of one LDH protein was 
calculated using the molecular weight of LDH divided by Avogadro’s number. 
 
Circular Dichroism of NPs with LDH 
 Measurements were carried out on a Jasco J-380 spectrometer.  Continuous scanning was 
used with a speed of 20 nm/min at increments of 1 nm from 200 nm to 260 nm.  Baseline 
correction was used with a 2 nm bandwidth.  All data are an average of three scans.  Phosphate 
buffer (150 mM) was used for baseline correction.  Samples (200 µL) consisted of FBP (1 mM), 
NAD+ (0.5 mM), LDH (0.6 mg/mL), and OxNPs (0.1 mg/mL) in phosphate buffer (150 mM).  
Measurements were carried out at room temperature and 37 oC.  For measurements performed at 
elevated temperatures, samples incubated for 10 min before measuring.  Controls were taken of 
LDH and OxNPs individually.  OxNP controls did not include any coenzymes and were taken in 
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phosphate buffer (150 mM).  LDH controls were performed with necessary coenzymes in 
phosphate buffer (150 mM). 
 
Response of OxNPs to Small Molecules 
Solutions (1 mL) were made consisting of OxNP (0.4 mg/mL) and small molecules (10 
mM) in nanopure water.  Samples incubated for 5-10 min at rt before being measured.  DLS 
measurements at 25 oC were performed in triplicate and the average was taken to determine the 
hydrodynamic diameter.  Samples were then incubated for 2 min at 37 oC before repeating 
measurements in triplicate.  It was visually apparent that particles were above LCST as the 
solution became turbid with turbidity increasing with the size of the particles.   
  The size change was converted to percent change in volume using the size of OxNP as 
the standard.  This was determined by calculating the volume of OxNPs with small molecules 
based on their Z-Average.  This was subtracted from the volume of OxNP and divided by the 
volume of OxNP using Equation 1.  OxNP percent change in volume was set as 0. 
Equation 1.  % 𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 = !"#$%& !" !"#$ !"#! !"#$$ !"#$%&#$!!"#$%& !" !"#$!"#$%& !" !"#$  
 
Response of OxNP-LDH Complexes to Small Molecules 
Solutions (1 mL) were made consisting of OxNP, FBP (1 mM), NAD+ (1 mM), and LDH 
(0.175 mg/mL).  The control sample consisted of NIPAm NPs (0.4 mg/mL) in water.  NAD+, 
FBP, and LDH were incubated together in water for 1 min before adding NP.  Samples were 
incubated at rt for 10 min before taking DLS measurements at 25 oC.  Measurements were 
performed in triplicate and the average was taken to determine the hydrodynamic diameter.  
Samples were then incubated for 2 min at 37 oC before repeating measurements in triplicate.  It 
15 
 
was visually apparent that particles were above LCST as the solution became turbid.  OxNP-
LDH complexes containing small molecules (10 mM) were prepared in a similar manner as 
above except small molecules were added at rt before measuring.  The same procedure was also 
followed for their DLS measurements. To test whether the addition of lactic acid was 
temperature dependent, a separate set of experiments were performed in which lactic acid was 
added at 37 oC to pre-mixed OxNP-LDH samples.  The same procedure as above was performed 
except OxNP-LDH solutions were not allowed to come to rt before lactic acid was added.  
Measurements were taken immediately at 37 oC.  The hydrodynamic diameter of NP was the 
same regardless of whether lactic acid was added at 25 oC or 37 oC. The percent change in 
volume is detailed by Equation 2.   
Equation 2. % 𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 = (!"#$%&  !"#$ !"# !"#! !"#$$ !"#$%&#$!!"#$%& !"#$ !"#)!"#$%& !"#$ !"#  
 
SEM of Inhibitor Functionalized NPs 
 A stock solution of OxNP (0.4 mg/mL) containing LDH (0.175 mg/mL), FBP (10 mM), 
and NAD+ (5 mM) was diluted ten-fold to a final concentration of 0.04 mg/mL OxNP and 
0.0175 mg/mL LDH. OxNP samples were prepared by drop casting a solution of OxNP in water 
(0.04 mg/mL, 10 µL) onto glass slides which were then heated in the oven at 150 oC until dry (1 
min). OxNP-LDH complexes were prepared by combining OxNP with LDH and coenzymes 
before diluting to concentrations previously mentioned. The solution was heated to 37 oC 
followed by drop casting onto glass slides and drying in the oven.  Samples of OxNP with LDH 
and lactic acid were prepared similarly, but a stock solution of OxNP with LDH was treated with 
lactic acid before dilution and drop casting.  The samples were sputter coated with a thin 
conductive layer (5 nm) of gold/palladium alloy (Polaron SC7620) to render the surface of the 
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NP electrically conductive for SEM imaging. Morphological characterization from the SEM (FEI 
Quanta 3D) was conducted using an electron voltage of 5 kV and a current of 53 pA.  
 
CryoTEM of OxNP-LDH Complexes 
Cryo-TEM samples were prepared by depositing 3 µl sample on a 200 mesh Cu grids with lacey 
carbon films (Electron Microscopy Sciences). All TEM grids were surface plasma treated for 20 
seconds using a Gatan Solarus Advanced Plasma Cleaning System 950 prior to use. An 
automated vitrification robot (Leica EM GP) was used for plunge vitrification in liquid propane. 
Cryo-TEM studies were performed on the JEOL JEM 2100F operated at 200 kV, 2k x 2k Gatan 
CCD camera. Gatan DigitalMicrograph. ImageJ was used for TEM image analysis. 
 
Results and Discussion  
Synthesis of Polymerizable Oxamate Derivative 
To impart NPs with affinity for LDH, we chose an oxamate derivative as a non-covalent 
inhibitor.  Oxamate is a competitive inhibitor of pyruvate for LDH with a similar Km as pyruvate 
Scheme 1: Synthetic pathway to polymerizable oxamate derivative 6. 
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for LDH (0.6 mM). 48  Since attachment of the inhibitor to a polymer backbone can restrict 
access to the LDH active site, we chose a six carbon atom tether for the oxamate inhibitor.  Our 
choice was based on the successful use of a solid-phase tethered oxamate derivative to purify 
LDH by affinity chromatography.49,50  In the chromatographic application, the oxamate moiety 
was coupled to a 1,6-hexanediamine spacer bound to a Sepharose bead.  Drawing from these 
results, an α,ω-1,6-diamine was functionalized with the oxamate group at the alpha position and 
an acrylamide at the omega position.  In this design, the alpha position can bind to LDH while 
the omega position can be covalently incorporated into the polymer backbone. 
The synthesis of the oxamate derivative 6 (Scheme 1) begins with mono-protection of 1,6 
hexanediamine with Boc-anhydride.  After purifying the mono-Boc diamine 2 via flash column 
chromatography, initial efforts to couple oxalic acid to the mono-Boc protected diamine 2 proved 
challenging, most likely due to the low electrophilicity of oxalic acid. The synthesis was 
simplified by switching to a more reactive, electrophilic acid chloride ethyl chlorooxoacetate. 
The free amine was coupled to ethyl chlorooxoacetate in the presence of Hünig’s base. The 
resulting mono-Boc oxamide 3 was then de-protected with TFA in DCM.  Following de-
protection, acryloylation of the free amine 4 was performed and ester 5 was purified via flash 
column chromatography.  The resulting ethyl ester 5 was then hydrolyzed using KOH in MeOH 
to produce the oxamate derived monomer 6.  
 
OxNP Synthesis 
The next step was incorporation of 6 into a NIPAm based polymer (Scheme 2).  The 
oxamate functionalized NP (OxNP) formulation consisted of 2 mol % polymerizable oxamate 
inhibitor 6, 2 mol % N,N’-methylenebis(acrylamide) (Bis) as cross-linker, and 96 mol % 
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NIPAm.  We assumed equal reactivity of NIPAm and the oxamate derivative since both are N-
substituted acrylamides.51  Under these conditions, the feed ratios should reflect the actual 
incorporation of the monomers in the polymer with random distribution of the oxamate 
derivative. This is further supported by the high yield of the polymerization (90%).  The OxNPs 
contain an additional permanent cross-linker, 2 mol % Bis. This low-level of covalent cross-
linking was included to ensure uniformly sized NPs form but low enough to remain responsive to 
changes in non-covalent cross-linking between the oxamate and LDH.52  Using a high 
concentration of Bis would restrict the polymer chains due to high cross-linking density, making 
it difficult to observe swelling. 
OxNPs were synthesized via precipitation polymerization in water and were purified by 
dialysis for 4 days to remove low molecular weight polymerization byproducts.  Following 
dialysis, the yield of polymers was determined by weighing a lyophilized aliquot of NP solution 
(90% yield).  Dynamic light scattering (DLS) was used to determine the hydrodynamic diameter 
of the particles and their polydispersity (Experimental Section).  Because NIPAm polymers 
exhibit an LCST ~ 32 oC30, particle size was measured at both 25 oC and 37 oC.  Below the 
LCST at 25 oC, the hydrodynamic diameter of OxNPs was 403±7 nm. At 37 oC, OxNP diameter 
decreased to 183±1 nm.  Since these particles have intended applications under physiological 
	
Scheme 2: NP synthesis utilizing 2 mol % polymerizable oxamate inhibitor, 96 mol % NIPAm, and 2 mol % Bis. 
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Figure 2: Quantification of LDH uptake by NPs. Centrifugation was performed to pull down NP-LDH 
complexes leaving the unbound protein free in supernatant. Bars represent amount of LDH leftover in 
supernatant. LDH Control corresponds to the maximum amount of LDH added to solutions.  NIPAm NP 
Control represents NIPAm NPs without oxamate inhibitor incubated with LDH. OxNP represent NIPAm NPs 
containing the oxamate inhibitor. The NIPAm NP Control showed no affinity for LDH while the OxNP 
demonstrated affinity for LDH.  
conditions, 37 oC was chosen for all measurements and experimental conditions.  Particle size 
was designed to be at or below 200 nm at body temperature to take advantage of the enhanced 
permeability and retention effect which promotes accumulation of nanoparticles in tumor tissues 
and to prevent encumbered circulation.53  
 
Quantification of LDH Uptake 
Following OxNPs synthesis the next step was to study LDH uptake by OxNPs.  The Km 
of oxamate for Bacillus stearothermophillus LDH is 0.6 mM.48  For LDH to serve as a cross-
link, it must bind to two or more oxamate groups.  This is realized under conditions where LDH 
is present as a homomeric tetramer with four discrete binding sites for oxamate groups.  These 
conditions are realized in the presence of NAD+ and fructose bisphosphate (FBP)49,50 which were 
present in all binding and uptake studies.  
OxNPs were incubated with LDH and its coenzymes FBP and NAD+ at room 
temperature to allow LDH to diffuse into the solvent swollen OxNPs and bind to the polymer 
bound oxamate groups.  After 30 min at room temperature, samples were heated to 37 oC for 10 
min.  Protein uptake was followed by centrifugation of OxNP-LDH complexes, which pelleted at 
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the bottom, leaving unbound LDH in the supernatant.  Protein concentration in the supernatant 
was determined using tryptophan fluorescence (Ex 280 nm, Em 342 nm) standardized against 
known concentrations of LDH.  The results are summarized in Figure 2.  Control experiments 
with unfunctionalized (no oxamate ligands) NIPAm NPs (98 mol % NIPAm and 2 mol % Bis) 
were included for comparison.  OxNPs (0.4 mg/mL) were calculated to bind 0.24 mg/mL of 
LDH in solution.  Control NPs showed negligible LDH uptake.  The wt:wt ratio of LDH to 
OxNPs was calculated to be 0.6 to 1.0. Using size exclusion multi-angle light scattering (SEC-
MALS), OxNP molecular weight was determined to be Mn of 2.276 x 108, Mw of 2.863 x 108, 
with a PDI of 1.26.  Using the known molecular weight of LDH (140 kDa for the tetramer) and 
OxNP (Mn of 2.276 x 108) one calculates approximately 1000 proteins per OxNP.  Despite this 
seemingly large number, less than 1% of the OxNP volume is taken up by LDH.  This was 
derived after determining the density of OxNPs (0.01 g/mL assuming the OxNPs are spherical) 
and using an assumed density of 1.3 g/mL for LDH.54  The density calculated for OxNPs does 
not include the water hydrating the polymer. 
 
Circular Dichroism (CD) Measurements 
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Non-covalent complexation of LDH with OxNPs and subsequent thermal cycling of the 
copolymer-protein complex could subject the protein to structural deformation and/or 
denaturation.  To evaluate this, we used CD spectroscopy to interrogate the OxNP-LDH 
complex.  Samples containing OxNPs alone, LDH alone (both at room temperature and 37 oC), 
OxNP-LDH complexes prepared at room temperature, and OxNP-LDH complexes prepared at 
room temperature followed by heating to 37 oC and cooling to room temperature were evaluated.  
In all cases, the alpha helical motifs in LDH were maintained (Figure 3).  OxNPs do not disrupt 
the secondary structure of LDH.  These results also indicate that the mechanical distortions from 
the polymer network’s contraction at 37 oC and expansion at room temperature are insufficient to 
produce detectable distortions in the non-covalently bound protein.  
 
Response of OxNP to Small Molecules 
Figure 3: CD Measurements of OxNPs and LDH.  CD was performed on OxNP alone and showed no signal.  
LDH was measured alone as a baseline.  OxNP-LDH complexes showed no significant difference from the 
baseline LDH.  After one heat cycle corresponds to measurements of OxNP-LDH complexes after being heated at 
37 oC for 10 minutes followed by cooling and measurement.  Each set of conditions demonstrated no denaturation 
occurring. 
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 To establish that the OxNP-LDH complexes are metabolite (lactate) responsive, several 
controls with OxNPs were performed.  DLS was used to monitor the change in size upon 
exposure of OxNPs to 10 mM solutions of lactic acid and several small molecules containing 
three or four carbons with either mono- or difunctional carboxylic acid and alcohol moieities at 
25 oC and 37 oC.  We found at 37 oC, pyruvic acid and oxalic acid caused aggregation (not 
swelling) of OxNPs, a conclusion supported by the high polydispersity (0.23±0.2 for pyruvic 
acid and 0.096±0.02 for oxalic acid).  Because these two molecules cause aggregation of OxNPs, 
they were not included in tests on OxNP-LDH complexes.  The response of OxNPs to lactic acid, 
diacetyl, propionic acid, and 2,3-butanediol are shown in Figure 3.  None of the small molecules 
significantly affected the size of OxNPs at 25 oC or 37 oC. 
 
Response of OxNP-LDH Complexes to Small Molecules  
A similar set of experiments was used to evaluate the response of the NP-protein 
complexes (OxNP-LDH complexes) to lactic acid and related small molecules.  To establish a 
baseline for the OxNP-LDH complexes, DLS measurements were run in water at 25 oC and 37 
Figure 4: Change in volume of OxNP exposed to small molecules at 25 oC and 37 oC.  All small molecules had a 
concentration of 10 mM.  Pyruvic acid and oxalic acid not shown. 
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oC.  At 25 oC, the complexes had an average size of 308±3 nm and 180±1 nm at 37 oC.  One 
important observation is the change in size of OxNP at 25 oC when LDH is added, the resulting 
complex is about 100 nm smaller than OxNP by itself (403±7 nm).  In contrast, NIPAm NPs do 
not experience a significant change in size when exposed to LDH at 25 oC (337±8 nm without 
LDH to 338±5 nm with LDH).  The decrease in size of OxNP after exposure to LDH at 25 oC is 
consistent with the uptake of tetrameric LDH and cross-linking the polymer backbone by binding 
at least two polymer-bound oxamate moieties.  It is reasonable that this shrinkage upon LDH 
cross-linking would be more apparent when performed in the solvent swollen state (25 oC).  
With the preceding benchmarks, the response of OxNP-LDH to small molecules was 
examined.  The conditions were similar to the previous experiment but an additional trial using 1 
mM of lactic acid was used to establish if OxNP-LDH complexes exhibit a concentration 
dependent response to lactic acid.  The results, shown in Figure 5, reveal there were no 
significant changes in volume of OxNP-LDH at 25 oC in the presence of any small molecules at 
10 mM concentration.   
At 37 oC the volume of OxNP-LDH complexes remained constant with one exception, 
lactic acid.  OxNP-LDH samples treated with 10 mM lactic acid at 37 oC experienced a 
Figure 5: Change in volume of OxNP-LDH complexes exposed to small molecules at 25 oC and 37 oC. Low 
lactic acid concentrations mirroring those found in healthy tissues (1 mM) do not cause a change in volume.  
High lactic acid concentrations (10 mM) cause a significant change in volume of OxNP-LDH complexes.  The 
box highlights the data point correlated to a large change in volume at 37 oC.  Other small molecules (10 mM) 
elicited no effect on OxNP-LDH complex volume. 
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significant increase in volume.  In contrast, 1 mM of lactic acid did not influence the volume of 
OxNP-LDH complexes.  We suggest the increase in OxNP-LDH complex volume upon 
exposure to 10 mM lactic acid arises from a combination of effects which include lactate 
displacement of the polymer bound oxamate moieties resulting in reduced cross-linking, 
electrostatic interactions, solvation, and possibly the catalytic activity of LDH.  Importantly, we 
note that 10 mM lactate was the only condition that induced a response.  
Due to the sensitivity of NIPAm systems to a variety of external factors, it is important to 
consider alternative explanations.  Although NIPAm is sensitive to changes in temperature55, 
pH56, and solvent ionic strength56,57, our observed increase in size is not accounted for by these 
factors.  However, we considered that pH may partially or indirectly contribute to the observed 
swelling.  Kratz et al.56 demonstrated a size increase of NIPAm NPs containing low loadings 
(1.25 mol % and 12.5 mol %) of acrylic acid (AAc) at low pH above their LCST.  Because the 
oxamate derivative incorporated into the polymer also has a carboxylic moiety, comparisons may 
be drawn between the 1.25 mol % loaded AAc NIPAm polymer and our system (OxNP).  Kratz 
attributed this observation to an expected collapse (desolvation) above LCST, but the collapsed 
NPs were prone to form somewhat uniform aggregates at low pH.56  This behavior was attributed 
to weak interparticle interactions.  They also observed that this was completely reversible. 
The pH of OxNP solutions drops significantly upon addition of lactic acid.  If the 
observed swelling of OxNP-LDH complexes in 10 mM lactic acid was solely pH dependent, one 
would have expected OxNPs to have exhibited the same response when exposed to lactic acid at 
37 oC.  This, however, was not observed.  Furthermore, at lactic acid concentrations similar to 
those found in healthy tissues in the body (1 mM), there is no response of OxNP-LDH 
complexes.  Once lactic acid concentrations exceed the normal range, only NP-protein 
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complexes (OxNP-LDH) responded.  We conclude therefore that the increase in size is due to a 
reduction in cross-linking brought about by competitive displacement of the polymer bound 
oxamate moiety by lactic acid. 
 Our main hypothesis is that lactic acid competitively displaces the polymer bound 
oxamate moiety, decreasing the cross-linking of the OxNP.  However, due to the complexity of 
this system, it is not unreasonable to think that other factors might also contribute.  For example, 
under 10 mM lactate conditions there could be “open” active binding sites on the homomeric 
tetramer LDH.48  The generation of pyruvic acid within the OxNP could potentially contribute to 
swelling of particles since the Kd of pyruvate is similar to that of oxamate, this could displace 
more oxamate moieties and further increase swelling.  Although this potential exists, this is not 
likely the most significant reason for swelling.  Experiments involving OxNP and OxNP-LDH 
complexes with pyruvic acid led to irreversible aggregation of particles, unlike what was 
observed with lactic acid.  This suggests there is something specific about lactic acid that does 
not lead to aggregation of particles, but instead leads to swelling.  
 
Scanning Electron Microscopy Imaging of NPs 
Scanning electron microscopy (SEM) was performed on OxNPs and lactic acid exposed 
OxNP-LDH complexes (Figure 6) to observe the size change of OxNP-LDH complexes in the 
Figure 6: SEM images of OxNPs. Left: OxNPs alone (a). Middle: OxNPs with LDH (b). Right: OxNPs with LDH and 
lactic acid (c).  
a. b. c. 
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presence of 10 mM lactic acid.  Samples were prepared by drop-casting a solution of OxNP in 
water onto glass slides then heated at 150 oC until dry.  To establish a point of reference, SEM 
images were taken of OxNPs (Figure 6a).  The size of OxNPs in Figure 6a and 6b (~ 160 nm) are 
roughly the same as those measured by DLS at 37 oC (183±1 nm).  These images are consistent 
with the experimental results obtained by DLS for lactic acid responsiveness.   
 
Cryo-Transmission Electron Microscope Images 
 To further characterize OxNP-LDH complexes, we employed cryo-transmission electron 
microscopy (cryoTEM) which enables the native state of the OxNPs to be imaged at high 
resolution (Figure 7).58  Due to the 100-fold difference in density between OxNPs (0.01 g/mL) 
and LDH (1.3 g/mL), the contrast will be dominated by the LDH particles.  At high defocus 
values (~10-20 microns), the OxNP-LDH complexes are easily identifiable and appear as 
homogeneous spheres with a 200 nm diameter (Figures 7a, highlighted with the dashed blue 
circles). This is consistent with the DLS measurements. At lower defocus values (~0.5 – 1 
micron) the OxNP-LDH complexes display extremely low contrast (Figure 7b, highlighted by 
the dashed blue circles), but the resolution is sufficient to identify individual LDH particles 
(Figure 7c). Due to the superposition of the LDH particles it is only possible to measure their 
individual diameter (~ 8 nm) close to the edge of the structures59, however, this is consistent with 
their previously measured RH values (~ 4.3 nm)60.   
27 
 
If LDH bound selectively to the surface, there would be a distinct and visible ring around 
the OxNPs; consequently, it was inferred that LDH distributed through the 3D volume of the 
OxNPs.  This is consistent with our observation that OxNPs contract when exposed to LDH by 
100 nm, and OxNP-LDH complexes swell when exposed to lactate.  If LDH were confined to the 
surface of the OxNPs, cross-linking and subsequent swelling would be minimized.   
 
  
Figure 7: cryoTEM images of OxNPs and OxNP-LDH complexes. Top left: image of OxNPs cluster (a.) Top right: 
image of OxNPs with protein bound (b.) Bottom left: Magnification of blue box from (b.) showing discrete LDH 
particles (c.) Bottom right: plot profile of selected protein particles (d.)  
 
a. b. 
c. d. 
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Conclusions  
In summary, a polymerizable oxamate LDH inhibitor 6 was synthesized and incorporated 
into lightly cross-linked NIPAm NPs, producing OxNPs.  LDH was efficiently taken up into 
OxNPs in the solvent-swollen state through incubation and non-covalent binding to the polymer 
bound oxamate moieties in the polymer backbone.  Protein loading was estimated to be 0.6 mg 
LDH/1 mg OxNP.  CD was used to demonstrate that OxNPs do not lead to distortion or 
denaturation of LDH’s secondary structure after being exposed to OxNPs below and above 
LCST as well as after one full heating cycle, which is important for cross-linking.  OxNP-LDH 
complexes showed a large swelling response in the presence of high lactic acid concentrations 
(10 mM), but none at low lactic acid concentrations (1 mM).  OxNP-LDH complexes exposed to 
lactic acid below LCST behave normally and remain the same size as without lactic acid.  Above 
the LCST, lactic acid treated OxNP-LDH complexes swell almost double their size at room 
temperature.  We have also used SEM to visualize OxNP-LDH complex’s response to lactic 
acid.  Through TEM, we have imaged OxNP-LDH complexes to further validate uptake.  We 
conclude that we have developed a metabolite-responsive system.  OxNP-LDH complexes swell 
in the presence of high lactic acid concentrations that mirror those found in tumors.  The 
influence of temperature and lactic on particle swelling only influences OxNPs when they are 
complexed with LDH. This supports our hypothesis that LDH acts as a cross-linker within the 
polymer and is displaced in the presence of lactic acid.  This system provides a platform for 
metabolite responsive NPs. 
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